Drug intelligence / Profile preview

NH280105

Development stage: Phase 1
Lead developer: Jiangsu Nhwa Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

NH280105 is an investigational small molecule drug being developed by Jiangsu Nhwa Pharmaceutical for the treatment of Alzheimer’s disease. It acts as an oral inhibitor of lipoprotein-associated phospholipase A2 (Lp-PLA₂), a target implicated in neuroinflammation and vascular pathology associated with Alzheimer’s disease. The drug is currently in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult participants.

Targets

PLA2G7 (Platelet-activating factor acetylhydrolase)

Beyond the preview

Go deeper on NH280105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NH280105.

Explore the full profile